Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
暂无分享,去创建一个
S. Yano | M. Kawada | K. Fukuda | H. Taniguchi | H. Mukae | S. Takeuchi | Tadaaki Yamada | S. Arai | H. Yamaguchi | Shuichi Sakamoto
[1] Y. Okada,et al. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer , 2017, Molecular Cancer Therapeutics.
[2] H. Saka,et al. Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. , 2016, Lung cancer.
[3] E. Hara,et al. Organ‐specific efficacy of HSP90 inhibitor in multiple‐organ metastasis model of chemorefractory small cell lung cancer , 2016, International journal of cancer.
[4] Y. Yatabe,et al. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer , 2015, Scientific Reports.
[5] J. Walters,et al. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. , 2015, The Cochrane database of systematic reviews.
[6] A. Arcaro. Targeted therapies for small cell lung cancer: Where do we stand? , 2015, Critical reviews in oncology/hematology.
[7] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[8] A. Nomoto,et al. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice , 2015, Cancer science.
[9] Liquid Biopsies. Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.
[10] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[11] T. Oguri,et al. Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells , 2014, Cancer science.
[12] S. Yano,et al. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells , 2014, Oncotarget.
[13] M. Salido,et al. Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[14] P. Meltzer,et al. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. , 2012, Current pharmaceutical design.
[15] T. Nakagawa,et al. Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer , 2012, Clinical Cancer Research.
[16] W. De,et al. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells. , 2011, The Journal of surgical research.
[17] S. Serrano,et al. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines , 2011, British Journal of Cancer.
[18] Y. Maehara,et al. Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer , 2010, Clinical Cancer Research.
[19] T. Nakagawa,et al. E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models , 2010, Cancer science.
[20] L. Shun. An Orally Available Small-Molecule Inhibitor of c-Met,PF-2341066,Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms , 2010 .
[21] G. Watanabe,et al. Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2009, Clinical Cancer Research.
[22] Y. Yatabe,et al. Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] Y. Yatabe,et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.
[24] R. Salgia,et al. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion , 2007, British Journal of Cancer.
[25] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[26] Shinji Yamazaki,et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.
[27] C. Rudin,et al. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. , 2007, Trends in molecular medicine.
[28] P. Comoglio,et al. Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.
[29] A. Ryan,et al. Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell–Depleted Severe Combined Immunodeficient Mice , 2005, Clinical Cancer Research.
[30] R. Salgia,et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.
[31] G. Kalemkerian,et al. Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.
[32] B. Zbar,et al. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. , 2002, The Journal of clinical investigation.
[33] R. Salgia,et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] K. Mori,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.
[35] S. Sone,et al. [Novel metastasis model of human lung cancer cells representing different histological types in SCID mice depleted of NK cells]. , 1997, Gan to kagaku ryoho. Cancer & chemotherapy.
[36] T. Tsuruo,et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells , 1996, International journal of cancer.
[37] J. Crawford,et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] G. Michalopoulos,et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. , 1991, Oncogene.
[39] J. Rubin,et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.